Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...
AriBio
AriBio Expands Alzheimer’s Drug AR1001 Licensing Deal with Samjin to Include China
AriBio Co., Ltd, a South Korea-based pharmaceutical company, has announced an expansion of its previous...
AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001
South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...